Co-Diagnostics Files 8-K on Security Holder Vote Matters
Ticker: CODX · Form: 8-K · Filed: Dec 5, 2025 · CIK: 1692415
| Field | Detail |
|---|---|
| Company | Co-Diagnostics, Inc. (CODX) |
| Form Type | 8-K |
| Filed Date | Dec 5, 2025 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: corporate-governance, shareholder-vote
Related Tickers: CDXC
TL;DR
CDXC filed an 8-K for a shareholder vote. Keep an eye on governance.
AI Summary
Co-Diagnostics, Inc. filed an 8-K on December 5, 2025, reporting on the submission of matters to a vote of security holders. The filing details administrative information about the company, including its incorporation in Utah and its principal executive offices located at 2401 S. Foothill Drive, Suite D, Salt Lake City, Utah.
Why It Matters
This filing indicates that Co-Diagnostics, Inc. is engaging in corporate governance processes involving shareholder decisions, which can impact company direction and shareholder rights.
Risk Assessment
Risk Level: low — The filing is procedural and relates to corporate governance, not immediate financial or operational risk.
Key Players & Entities
- Co-Diagnostics, Inc. (company) — Filer of the 8-K report
- December 5, 2025 (date) — Date of the earliest event reported
- Utah (location) — State of incorporation
- 2401 S. Foothill Drive, Suite D, Salt Lake City, Utah 84109 (address) — Principal executive offices
FAQ
What specific matters were submitted to a vote of security holders?
The filing states that the report concerns 'Submission of Matters to a Vote of Security Holders' but does not detail the specific matters in the provided text.
When was the earliest event reported in this 8-K filing?
The earliest event reported was on December 5, 2025.
In which state is Co-Diagnostics, Inc. incorporated?
Co-Diagnostics, Inc. is incorporated in Utah.
What is the principal executive office address for Co-Diagnostics, Inc.?
The principal executive offices are located at 2401 S. Foothill Drive, Suite D, Salt Lake City, Utah 84109.
What is the IRS Employer Identification Number (EIN) for Co-Diagnostics, Inc.?
The IRS Employer Identification Number for Co-Diagnostics, Inc. is 46-2609363.
Filing Stats: 451 words · 2 min read · ~2 pages · Grade level 13.3 · Accepted 2025-12-05 16:30:32
Key Financial Figures
- $0.001 — ch registered Common Stock, par value $0.001 per share CODX The Nasdaq Capital M
Filing Documents
- form8-k.htm (8-K) — 35KB
- 0001493152-25-026385.txt ( ) — 195KB
- codx-20251205.xsd (EX-101.SCH) — 3KB
- codx-20251205_lab.xml (EX-101.LAB) — 33KB
- codx-20251205_pre.xml (EX-101.PRE) — 22KB
- form8-k_htm.xml (XML) — 4KB
From the Filing
UNITED SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): December 5, 2025 CO-DIAGNOSTICS, INC. (Exact name of small business issuer as specified in its charter) Utah 1-38148 46-2609363 (State or other jurisdiction of (Commission (IRS Employer incorporation or organization) File Number) Identification Number) 2401 S. Foothill Drive , Suite D , Salt Lake City , Utah 84109 (Address of principal executive offices) (801) 438-1036 (Issuer's telephone number) Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act: Title of each class Trading Symbol(s) Name of each exchange on which registered Common Stock, par value $0.001 per share CODX The Nasdaq Capital Market Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (240.12b-2 of this chapter). Emerging growth company If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. Item 5.07 Submission of Matters to a Vote of Security Holders On December 5, 2025, Co-Diagnostics, Inc. (the "Company"), held a special meeting of shareholders at which the following matters were voted on: Proposal No. 1 : The proposal to approve an amendment to the Company's Articles of Incorporation to effect a reverse stock split of the Company's issued and outstanding shares of common stock, at a ratio of not less than 1-for-2 and not greater than 1-for-30, such final ratio to be determined by our Board at any time within twelve months, without further approval or authorization of our shareholders, was approved. For Against Abstain 26,465,960 4,213,378 194,746 SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized. CO-DIAGNOSTICS, INC. Date: December 5, 2025 By: /s/ Brian Brown Name: Brian Brown Title: Chief Financial Officer (Principal Financial and Accounting Officer)